Rosettedetect: advanced AI for rosette detection in multichannel imagery
RosetteDetect, a proprietary AI model by Neurosetta, excels in detecting rosettes with over 90% accuracy, specificity, and sensitivity, offering a gold-standard solution in toxicity and drug discovery through advanced convolutional neural networks.
Overview
RosetteDetect is an innovative AI-driven solution developed by Neurosetta, designed to identify rosettes in multichannel and multi-slice imagery with remarkable precision. Leveraging advanced convolutional neural networks, RosetteDetect achieves over 90% accuracy, specificity, and sensitivity, positioning it as a gold standard in the toxicity and drug discovery industries. By utilizing cloud computing, Neurosetta has significantly accelerated the development and iteration process, transforming what traditionally took weeks into mere days.
Technical specifications
RosetteDetect employs a sophisticated AI model based on convolutional neural networks, trained on an extensive dataset of RosetteArray imagery. The model processes 6182 image sets, with 588 dedicated to training and 5594 for testing, exhibiting exceptional performance metrics such as a high f1 score. The segmentation component of the model has been rigorously validated, resulting in a mean average error of just 0.03 m² in rosette area measurements, using a truthed dataset of 128 image sets.
Technology readiness level
Currently at Technology Readiness Level 5, RosetteDetect has proven efficacy in controlled testing environments. Future validation will involve adapting the model to new datasets, employing cloud computing protocols and advanced data analysis techniques to ensure continued accuracy and reliability. Neurosetta is committed to utilizing top-tier cloud computing resources to optimize this adaptation process.
About Neurosetta
Neurosetta is a biotechnology company that commercializes RosetteArray technology, a human stem cell-derived platform designed for high-throughput screening and disease modeling. The company utilizes micropatterned well plates, which incorporate specialized surface chemistry to induce the formation of neural tissues such as brain and spinal cord rosettes. By seeding these plates with human pluripotent stem cells or neuromesodermal progenitors, the platform enables researchers to study early human neurodevelopment, assess chemical or drug toxicity, and explore the impacts of genetic backgrounds in a reproducible and scalable manner.
This technology provides pharmaceutical, chemical, and research organizations with a tool to identify potential neurodevelopmental risks earlier in the development pipeline, potentially reducing costs and minimizing safety vulnerabilities. Neurosetta offers both standardized assays and custom services, including drug discovery screens and the development of patient-derived models for neurological conditions. The company holds exclusive rights to the underlying patented technology and operates from the Wisconsin Institute for Discovery, focusing on advancing precision medicine and chemical safety.
Inquire about this partnering listing
Industry applications
delivered to your inbox.